Why Your HA Filler Is Not in the Korean Drug Register

A buyer does the responsible thing. They take the name of a Korean hyaluronic acid filler, go to the Ministry of Food and Drug Safety approval register, search for it, and find nothing. No licence, no holder, no grant date. The natural conclusion is that something is wrong with the product. The actual conclusion is that they are reading the wrong register.

Korean HA fillers are not drugs. They are medical devices, and Korea keeps devices in a separate register with separate fields and a separate numbering scheme. Absence from the drug register is not a finding about a filler. It is the expected result, and a filler that did appear there would be the surprising case. This article shows what actually sits in each register, using full sweeps of both taken on 7 August 2026.¹

What hyaluronic acid looks like in the drug register

The drug register is not empty on this molecule. Queried on sodium hyaluronate as an active ingredient, it returns 302 records, of which 266 are live. That is a substantial category. It is simply not the category anyone shopping for a filler is looking for.

Read the classes rather than the counts and the picture resolves immediately. The 141 non-injectable ophthalmic licences are eye drops. The 19 injectable ophthalmic licences are surgical viscoelastics. The 94 filed as metabolic agents are the joint injections. Every one of the 266 is a real product with a real licence, and none of them is a filler.

The oldest live injectable licence in that set dates to 8 April 1993, and the oldest live non-injectable to 31 May 1996. So Korea has been licensing sodium hyaluronate as a drug for more than thirty years, which is longer than it has been licensing fillers at all. The molecule was never the thing that determined which register a product lands in.

Where fillers actually sit

HA fillers are licensed in the medical device register under a product category whose Korean name translates as tissue repair biomaterial. Swept in full on the same day, that category returns 612 records: 461 live and 151 withdrawn or discontinued.

Those 461 live licences are held by 105 companies. That is a crowded category by any measure, and the ratio is worth pausing on: an average of four to five licences per holder, with the largest domestic holder carrying twenty-four and the next three carrying seventeen, sixteen and sixteen. The Korean filler market is not a handful of manufacturers with long catalogues. It is a wide field with a mild concentration at the top.

The withdrawal figure deserves the same attention. One record in four in this category is no longer live. Withdrawal is an ordinary administrative event and carries no implication about any product's safety, but the rate tells you something structural: licences in this category are taken out and given up at a pace the drug register does not match. A licence you were shown last year is worth re-checking rather than assuming.

One caveat on that number

The category is called tissue repair biomaterial, not HA filler, and the distinction is not pedantic. It is defined by what a product does structurally rather than by what it is made of, so it holds more than hyaluronic acid. The oldest record in the whole category is not a filler in the sense anyone means today: an imported collagen product licensed in June 1999 and withdrawn in 2005, followed within months by three more imports from European and Japanese makers, all since withdrawn.

So 461 live licences is the correct count for the category HA fillers belong to, and it is an overcount if you read it as the number of HA filler licences specifically. We report it as the former because that is what the register actually indexes: there is no separate HA filler category to query. Anyone quoting a tighter figure is either filtering by something the register does not record or counting brands rather than licences, and the two are very different numbers.

The useful consequence is a check rather than a caution. When a supplier cites a licence, the category name on that licence tells you which register field they are drawing on, and a filler that does not sit in this category is a product worth asking more questions about.

The device register asks different questions

This is the part that matters most for anyone trying to verify a filler using habits learned from injectables. The two registers do not record the same facts, so a check that works in one has no equivalent in the other.

Two of those rows have no counterpart on the drug side at all, and they are the two that do the most work.

The licence number tells you where it was made

Korean device licence numbers carry a prefix that encodes how the licence was obtained. One prefix marks domestic manufacture and another marks import. It sits at the front of the number printed on the carton, so it is legible before any database lookup at all.

Across the 461 live licences in this category, the split is lopsided:

The category is overwhelmingly a domestic manufacturing category. That is not a marketing impression, it is the register's own count, and it explains something buyers notice without being able to name: the reason Korean filler catalogues are so deep is that Korean companies hold the licences rather than distributing someone else's.

The import side is small and highly recognisable. Its licences are concentrated in the Korean subsidiaries of the large international filler companies, with the single largest holding ten and the next holding seven. Those are the global brands entering Korea, which is the mirror image of the traffic most readers of this site are thinking about.

Every import names its manufacturer, most domestic licences do not

The device register carries a manufacturing site field separate from the licence holder, and it is filled in with striking consistency along exactly one line. All 34 import licences name a manufacturing site. Of the 427 domestic licences, only 31 do.

The pattern makes sense once stated: where the holder is a Korean subsidiary and the maker is a foreign plant, the two are different entities and the register records both. Where a Korean manufacturer holds its own licence, holder and maker are the same and the field adds nothing. So a filled manufacturer field on a Korean filler licence is a fairly reliable signal that you are looking at an import.

One incidental detail from the same field is worth reporting because we have written about the identical problem in our own records. The same foreign manufacturer appears under two different capitalisations of its own name, counted separately by any naive query. Register data is entered by people over decades, and normalising it is part of reading it rather than something the source does for you.

The category began as an import category

Sort the live licences by grant year and the direction of travel is unambiguous.

For the first seven years of the category there was not a single live domestic licence. Every filler licensed in Korea was brought in from somewhere else. The first domestic grant lands in April 2010, parity arrives the same year, and from 2015 onward the import column effectively closes: three of those years recorded no new import licence at all.

That arc is the entire reason a Korean filler industry exists to buy from. It also sets a limit on a common assumption. A Korean filler is not Korean because Korea is where fillers come from. It is Korean because, over about fifteen years, Korean companies took out their own licences instead of importing under someone else's.

One qualification on this table, stated plainly because it affects how far the figures can be pushed. The public device dataset we swept thins out sharply after 2023, and the same thinning appears in unrelated device categories we checked as controls. Grants from 2024 onward are therefore not reliably represented, and nothing above should be read as a claim about the last two years. Every figure in this article describes licences granted through 2023.

Fillers are not traceability-managed devices

The device register carries a flag marking whether a licence falls under Korea's traceability management scheme, which imposes additional obligations for following individual units after they leave the manufacturer. Across all 461 live licences in this category, the flag is set on zero.

Because a universal negative invites the suspicion that the field is simply unpopulated, we checked it against controls. Silicone gel breast implants return the flag set on 13 of 19 records. Implantable cardiac pacemakers return it set on 40 of 40. The field works, and the zero is a real property of this category rather than a gap in the data.

What follows is narrow and worth stating without inflation. It does not mean fillers are untraceable: lot numbers, expiry dates, and manufacturer records all exist and are the ordinary basis of a recall. It means the additional statutory tracking layer that applies to certain implanted devices does not apply here, so the practical reachability of any given unit rests on the distribution chain that handled it. For a cross-border buyer that is an argument for documented channel rather than an argument about the product, and it is the same argument we make in what a counterfeit injectable actually costs.

What to check instead

Putting it together, verifying a Korean filler is a different exercise from verifying an injectable drug, and the habits do not transfer cleanly.

• Use the device register, not the drug register. A filler will never appear in the latter. Its absence there is not evidence of anything.
• Read the licence number prefix. It tells you domestic manufacture or import before you look anything up, and it is printed on the carton.
• Expect no supply classification. There is no prescription-only field on a device licence. Any listing citing one for a filler is citing something that does not exist, unlike the situation for enzymes and injectables where the classification is real and uniform.
• Name the holder, and check it is still live. With one record in four withdrawn, currency matters more here than in categories with lower churn.
• Do not read the manufacturer field as a quality signal. It is filled almost exclusively on imports. Its absence on a domestic licence means holder and maker are the same company.
• Confirm destination-market status separately. Korean device licensing governs Korea. What your own market permits is decided by your own authority, and device rules frequently differ from drug rules within the same country.

How KSTATION applies this

Licensing and manufacturer details are checked against the relevant MFDS register before a product is listed, which for fillers means the device register rather than the drug register. Where a supplier sheet and the register disagree, the register wins and the listing is corrected. We stock officially sourced products only, and the method is set out in our Editorial & Sourcing Policy.²

Our stocked HA range sits under derma fillers and body volume augmentation, with lines such as HYALDEW and Hyalmass. For the material properties that distinguish one filler from another once the licensing question is settled, see reading an HA filler and cross-linked versus uncross-linked HA. For how the Korean system fits together across both registers, see inside Korea's MFDS regulation.

Frequently asked questions

Disclaimer. This article is general educational information and is not medical advice. It describes how products in this category are classified, licensed, and recorded in public registers; it makes no claim about what any product does, achieves, or is suitable for, and it is not a selection, preparation, or administration guide. Products referenced are intended for professional use by trained practitioners. Regulatory and customs requirements vary by country and change over time; confirm current requirements with the relevant authority.